title: Hydroxocobalamin for severe acute cyanide poisoning by ingestion or inhalation.
abstract: This chart review was undertaken to assess efficacy and safety of hydroxocobalamin for acute cyanide poisoning. Hospital records of the Fernand Widal and Lariboisière Hospitals were reviewed for intensive care unit admissions with cyanide poisoning for which hydroxocobalamin was used as first-line treatment from 1988 to 2003. Smoke inhalation cases were excluded. Hydroxocobalamin (5-20 g) was administered to 14 consecutive patients beginning a median 2.1 hours after cyanide ingestion or inhalation. Ten patients (71%) survived and were discharged. Of the 11 patients with blood cyanide exceeding the typically lethal threshold of 100 micromol/L, 7 survived. The most common hydroxocobalamin-attributed adverse events were chromaturia and pink skin discoloration. Severe cyanide poisoning of the nature observed in most patients in this study is frequently fatal. That 71% of patients survived after treatment with hydroxocobalamin suggests that hydroxocobalamin as first-line antidotal therapy is effective and safe in acute cyanide poisoning.
authors.affiliation: University of Texas Health Science Center, San Antonio, TX 78229, USA.
authors.forename: Stephen W
authors.initials: SW
authors.lastname: Borron
authors.forename: Frédéric J
authors.initials: FJ
authors.lastname: Baud
authors.forename: Bruno
authors.initials: B
authors.lastname: Mégarbane
authors.forename: Chantal
authors.initials: C
authors.lastname: Bismuth
mesh_terms: D000328:Adult; D000931:Antidotes / Q000627:therapeutic use*; D003486:Cyanides / Q000008:administration & dosage / Q000506:poisoning*; D005260:Female; D015600:Glasgow Coma Scale; D006801:Humans; D006879:Hydroxocobalamin / Q000627:therapeutic use*; D008297:Male; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000931:Antidotes; D003486:Cyanides; D006879:Hydroxocobalamin